Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pre-diabetes (pre-DM)
100%
Exenatide
53%
Antidiabetic Effect
53%
GLP-1 Analogue
46%
Interleukin-6
46%
Randomized Controlled Trial
46%
Glucagon-like
46%
Interleukin-6 Signaling
46%
Vasodilation
46%
Thermogenic
46%
Adipocyte
46%
Obese Men
46%
Liraglutide
26%
Post-meal
23%
Saxagliptin
20%
Placebo
20%
Forearm Blood Flow
20%
Adipose Tissue
19%
Thermogenesis
19%
IL-6 Receptor Signaling
13%
Glucagon
13%
STAT3 Activation
13%
Chronic Therapy
13%
Postprandial Effect
11%
High-fat Meal
10%
Adipocyte Browning
6%
Thermogenic Adipocytes
6%
Exenatide Extended-release
6%
Acute Therapy
6%
Glucagon-like peptide-1 (GLP-1)
6%
Systemic Circulation
6%
Six-axis
6%
Inflammatory Markers
6%
Monocytes
6%
Knock-in Mouse Model
6%
Interleukin-6 Receptor (IL-6R)
6%
Mouse Model
6%
Brown Adipose Tissue
6%
Antibody Treatment
6%
Glucose Utilization
6%
Pre-meal
6%
Weight Loss
6%
Triglycerides
6%
Receptor Knockout
6%
Insulin
6%
Obesity
6%
Free Fatty Acids
6%
Receptor Signaling
6%
Blocking Antibodies
6%
IL-6 Receptor
6%
Immunology and Microbiology
Adipocyte
46%
Interleukin 6
46%
Antidiabetic Activity
46%
Adipose Tissue
21%
Thermogenesis
12%
STAT3
8%